TABLE 2.
Implementation Metrics
| Turnaround Time | Number of Days, Median (IQR) |
|---|---|
| Overall turnaround time | 6 (3-7) |
| Time from collection to receipt | 1 (1-2) |
| Time from receipt to result | 3 (2-6) |
| Timing of Testing | Number of Patients (N = 757), No. (%)f |
| Pretreatment testing | 621 (82) |
| DPYD variant carrier rate | 32 (5.2) |
| Resulted by treatment start date | 561 (90) |
| Reactive testinga | 136 (18) |
| DPYD variant carrier rate | 13 (9.6) |
| Collected on treatment start date | 59 (43) |
| Fluoropyrimidine Modifications in DPYD Variant Carriers Upon Result Return | Number of Carriers (n = 45), No. (%)f |
| Pretreatment testing | 32 (71) |
| Dose reducedb | 27 (84) |
| Not startedc | 5 (16) |
| Reactive testing | 13 (29) |
| Dose reduced | 9 (69) |
| Discontinuedd | 1 (7.7) |
| No changee | 3 (23) |
a
Two patients initially had the sample collected before treatment but due to insufficient DNA required sample recollection after treatment, and results were returned after treatment start.
b
One pretreatment testing carrier whose results were returned after treatment start received a dose reduction starting in cycle 2. This patient was not included in the Outcomes Cohort due to the cutoff date.
c
Three died before treatment started, one declined chemotherapy, and one had treatment avoided due to variant and hepatic impairment.
d
Due to variant and grade 3 toxicities.
e
Tolerating therapy per provider.
fPercentages may not add up to exactly 100% due to rounding.